| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose.
|
Eur J Nucl Med
|
1997
|
1.42
|
|
2
|
Comparison of three different methods for radiolabelling human activated T lymphocytes.
|
Eur J Nucl Med
|
1997
|
1.18
|
|
3
|
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation.
|
Eur J Nucl Med
|
1998
|
1.11
|
|
4
|
Genome scan implicates adhesion biological pathways in secondary leukemia.
|
Leukemia
|
2007
|
1.04
|
|
5
|
Structure, function and gene expression of epithelial mucins.
|
Tumori
|
1997
|
0.93
|
|
6
|
Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
|
J Nucl Med
|
1998
|
0.93
|
|
7
|
A simple loop method for the automated preparation of (11C)raclopride from (11C)methyl triflate.
|
Appl Radiat Isot
|
2001
|
0.91
|
|
8
|
The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas.
|
Tumori
|
1997
|
0.88
|
|
9
|
Pattern of mucin gene expression in normal and neoplastic lung tissues.
|
Anticancer Res
|
1996
|
0.87
|
|
10
|
A new, convenient method for the preparation of 4-[18F]fluorobenzyl halides.
|
Appl Radiat Isot
|
2000
|
0.83
|
|
11
|
Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.
|
Clin Pharmacol Ther
|
2008
|
0.82
|
|
12
|
Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.
|
Q J Nucl Med Mol Imaging
|
2010
|
0.81
|
|
13
|
Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer.
|
Int J Oncol
|
1996
|
0.81
|
|
14
|
A simple and semi-automated system for increasing the recovery of aqueous [18F] fluoride from target.
|
Anticancer Res
|
1998
|
0.81
|
|
15
|
Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.78
|
|
16
|
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC).
|
Oncol Rep
|
1996
|
0.77
|
|
17
|
Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: results of a multicenter trial.
|
Int J Biol Markers
|
1994
|
0.77
|
|
18
|
CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases.
|
Eur J Cancer
|
1992
|
0.77
|
|
19
|
Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology.
|
Int J Biol Markers
|
1992
|
0.77
|
|
20
|
Mucin gene expression in lung cancer tissues.
|
Int J Biol Markers
|
1995
|
0.75
|
|
21
|
MLL methylation is not likely a common mechanism for therapy-related AML.
|
Leukemia
|
2005
|
0.75
|
|
22
|
Reliability of immunoradiometric assays for sex-hormone binding globulin, androstenedione, 17-Beta estradiol and tumor-markers cea and cb15.3 to assess the biological response of megestrol-acetate treatment in patients with advanced breast-cancer.
|
Int J Oncol
|
1994
|
0.75
|
|
23
|
PSA-alpha 1-antichymotrypsin determination in patients with benign prostatic hyperplasia and prostatic cancer.
|
Int J Biol Markers
|
1993
|
0.75
|
|
24
|
The need to define the substances measured in tests for cytokeratins.
|
Int J Biol Markers
|
1995
|
0.75
|
|
25
|
Mucin-like carcinoma-associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan.
|
Int J Biol Markers
|
1993
|
0.75
|
|
26
|
Placental alkaline phosphatase in the cerebrospinal fluid of patients affected by pineal region neoplasms.
|
Int J Biol Markers
|
1992
|
0.75
|
|
27
|
CA 15.3 as a signal of undetectable breast cancer metastases in a follow-up period of 4 years.
|
Int J Biol Markers
|
1992
|
0.75
|
|
28
|
Tumour marker evaluation in patients with lung cancer.
|
Scand J Clin Lab Invest Suppl
|
1995
|
0.75
|
|
29
|
Lack of tissue-specificity of mucin markers in a lung-cancer model - biochemical approach.
|
Int J Oncol
|
1994
|
0.75
|
|
30
|
The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects.
|
Toxicol In Vitro
|
2001
|
0.75
|
|
31
|
Radiopharmaceuticals for breast cancer imaging.
|
Tumori
|
1997
|
0.75
|
|
32
|
The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan.
|
Tumori
|
1997
|
0.75
|
|
33
|
EIA/IRMA test for cytokeratin 19 determination.
|
Int J Biol Markers
|
1994
|
0.75
|
|
34
|
The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma: the experience of the Istituto Tumori of Milan.
|
Int J Biol Markers
|
1992
|
0.75
|
|
35
|
Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer.
|
Oncol Rep
|
1995
|
0.75
|